Objectives
To identify the prenatal predisposing factors related to neonatal lupus erythematosus (NLE).
Materials and Methods
A retrospective case-control study was made of 131 pregnant women with ...positive anti-Ro or anti-La autoantibodies and known neonatal outcomes between January 2002 and December 2019 at Siriraj Hospital, Bangkok, Thailand. There were 101 unaffected neonates and 30 NLE cases confirmed postnatally. Demographic and clinical data of the mothers and neonates with and without NLE were statistically compared.
Results
NLE was diagnosed in 30 out of 131 cases. A multivariate analysis identified the following significant factors for NLE: maternal anti-La antibodies (odds ratio (OR), 3.591; p = 0.030); and maternal treatment with either hydroxychloroquine (OR, 0.082; p = 0.001) or prednisolone (OR, 0.136; p = 0.017). Of the significant variables examined in the multivariate analysis models, high levels of maternal anti-La antibodies were found to be the strongest predictor of noncardiac NLE (OR, 4.558; p = 0.032), while a female baby was significantly higher in pregnancies complicated by cardiac NLE (OR, 5.374; p = 0.046). Hydroxychloroquine still provided a protective effect for both cardiac and noncardiac NLE (p = 0.039 and 0.032, respectively).
Conclusions
The maternal anti-La antibodies were a beneficial predictor for NLE, especially as their high titers were influentially associated with noncardiac features. A female fetus seemed to present an increased risk for developing a congenital heart block. Nevertheless, the treatment with hydroxychloroquine during the pregnancies demonstrated a potentially protective factor against both cardiac and noncardiac manifestations.
Full text
Available for:
DOBA, IZUM, KILJ, NUK, OILJ, PILJ, PNG, SAZU, UILJ, UKNU, UL, UM, UPUK
Background and Aim: During the Covid-19 pandemic, the knowledge, attitudes, and practices about COVID-19 infection in gynecologic cancer patients were still limited. This study aimed to explore these ...issues.Methods: Gynecologic cancer patients who attended our gynecologic oncology unit between February and June 2022 were invited to a cross-sectional survey using a WHO survey tool. Results: 363 patients participated with 20.9% undergoing treatment and receiving the COVID-19 vaccine significantly less than the surveillance participants (85.4% vs.57.9%, P < 0.01). Forty-eight participants developed a COVID-19 infection. The most common vaccine used for the two first doses was AstraZeneca. Regarding attitudes issues, most participants felt health literacy was obtained easily. They considered that they had a moderate probability to have severe symptoms of COVID-19 infection and almost all knew the proper behavior for prevention. The participant reported little stress and most trusted healthcare workers and family doctors. They agreed with lifting regular rules to control the COVID-19 pandemic. The other opinions that were significantly higher in participants who did not receive the vaccine versus those who received the vaccine, were as follows: “If everyone is vaccinated, no need for me to vaccinate”, “the stress made me not want to vaccinate”, “no need to vaccine due to rare disease” and “the vaccine is unsafe”. Conclusion: Gynecologic cancer patients who were under treatment received the COVID-19 vaccine less than those under surveillance. Most participants revealed a good attitude toward this pandemic. However, unvaccinated participants were concerned about the severe side effects of the vaccine.
